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BACKGROUND AND AIMS  
 
Primary immunodeficiencies comprise more than 200 different disorders that 
affect the development and the functions of the immune system.  In most cases 
primary immunodeficiencies are monogenic disorders that follow a simple 
mendelian inheritance.  Primary immunodeficiencies are rare and have an overall 
prevalence of approximately 1:10.000 live births and are classified according to 
the component of the immune system that is primarily involved. 
Primary immunodeficiencies are characterized by increased susceptibility to 
severe infections with distinctive susceptibility to various types of pathogens 
depending on the nature of the immune defect.  The study of primary 
immunodeficiencies has led to better understanding the mechanisms that are 
involved in adaptive immune responses and innate immunity.  Primary 
immunodeficiencies are classified according to the component of the immune 
system that is primarily involved including T, B, natural killer (NK) lymphocytes, 
phagocytic cells and complement proteins (Figure 1) (1).  
 
Figure 1. Genetic defects in Primary Immunodeficiencies 
 
Severe combined immunodeficiencies (SCIDs) represent a spectrum of 
illnesses with similar clinical manifestations, which can be subdivided into several 
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categories on the basis of the presence or absence of T cells, B cells and Natural 
Killer (NK) cells.  These are relatively rare diseases, collectively occurring in 
1:100.000 live births (2?5).  Without effective treatment, patients typically die of 
opportunistic infections before 1 year of age.  SCID can be cured by bone marrow 
transplantation in most instances (4).  Various mechanisms of these diseases have 
been described.  Impaired survival of lymphocyte precursors is observed in 
reticular dysgenesis (RD) and in adenosine deaminase (ADA) deficiency.  In RD 
the mutations of the adenylate kinase 2 gene (AK2) result in increased apoptosis 
of myeloid and lymphoid precursors.  As a consequence, patients with RD show 
marked lymphopenia and neutropenia (6, 7).  ADA deficiency is characterized by 
the accumulation of high intracellular levels of toxic phosphorylated metabolites 
of adenosine and deoxyadenosine that cause apoptosis of lymphoid precursors in 
the bone marrow and thymus (8, 9).  Deficiency in expression or function of the γ 
common (γc) cytokine receptor subunit shared by the receptors for IL?2, IL?4, IL?
7, IL?9, IL?15 and IL?21 causes the X?linked form of SCID (X?SCID), 
characterized by the complete absence of both T and NK lymphocytes (10).  
Deficiency in JAK3, which is normally associated with the cytoplasmic region of 
γc, results in an identical phenotype (10).  Deficiency in either RAG1 or RAG2 
(the lymphoid?specific recombination?initiating elements) or Artemis (a factor 
involved in the nonhomologous end?joining repair pathway) leads to defective 
V(D)J rearrangements (5) and thereby thymocyte and pre?B cell death.  Defective 
pre?TCR and TCR signaling was also described.  Pure T?cell deficiencies are 
caused by defects in either a CD3 subunit (such as CD3δ, CD3ε or CD3ζ) (5) or in 
the CD45 tyrosine phosphatase (11), key proteins involved in pre?TCR and/or 
TCR signaling at the positive selection stage.  Other T?cell immunodeficiencies in 
the SCID group, such as ZAP?70 deficiency (12), CD3γ deficiency (13), HLA 
class II expression deficiency (14), purine nucleoside phosphorylase deficiency 
(15), ligase IV or Cernunnos deficiency (16) and Omenn syndrome (17) were 
included.   
Most of the genes, whose alterations underlie SCIDs, are selectively expressed 
in hematopoietic cells.  In the 1996, for the first time, a novel form of SCID was 
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described, defined as Nude/SCID syndrome (18).  This syndrome represents the 
first example of SCID not primarily related to an abnormality of the 
hematopoietic cell.  The disease is due to a molecular alteration of the 
transcription factor FOXN1, which is selectively expressed in thymic and 
cutaneous epithelia (19).   
Some forms of primary immunodeficiencies show a more complex phenotype 
in which immune dysregulation is only one of multiple components of the disease 
phenotype.  Several immunodeficiencies are caused by defects in mechanisms of 
DNA breaks repair.  Ataxia?telangiectasia is an autosomal recessive disease 
caused by mutations of the ataxia?telangiectasia mutated gene (ATM).  Patients 
with ataxia?telangiectasia have ataxia, ocular telangiectasia, increased risk of 
infections and tumors.   
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This thesis reports the results obtained during my PhD course in “Human 
Reproduction, Development and Growth” (XXIV Cycle) from 2008 to 2011.   
My PhD programme has been focused in the study of the following lines of 
research: 
? Role of γc in cell cycle progression, strongly related to its cellular 
amount and Growth Hormone Receptor (GH?R) signaling, defining the basis 
of the physiological interaction between endocrine and immune systems; 
? Molecular and clinical characterization of the human Nude/SCID 
phenotype and study of functional role of transcription factor FOXN1 in the 
T?cell ontogeny and in the nervous central system development; 
? Effects of steroid treatment in patients affected with Ataxia?
Telangiectasia; 
? Immunodeficiencies associated with unidentified molecular 
defects. 
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CHAPTER I 
“X?linked Severe Combined Immunodeficiency  
due to mutations of γc” 
 
X?SCID is the most common form of SCID, accounting for approximately half of 
all cases and is the main form of T?B+NK?, in which T cells and NK cells are 
absent or profoundly diminished in number, whereas B?cell number is normal.   
X?SCID is generally fatal unless an immune system can be reconstituted.  The 
best current treatment for X?SCID is bone marrow transplantation (BMT) from an 
HLA?matched related donor.  This therapeutic approach confers to children 
affected by SCID at least a 70% chance of cure.  Moreover, the use of a not fully 
HLA?matched donor increases the immunologic complication such as graft?
versus?host disease (GVHD) associated with a potential long?term decline in 
immune cell function.  X?SCID has recently been successfully treated by gene 
transfer therapy to hematopoietic stem cells, but serious adverse events have also 
occurred.  Two separate trials for X?SCID have shown the clinical feasibility of 
introducing a therapeutic gene into hematopoietic stem cells (20).  The deficiency 
was restored and lymphocyte development was no longer blocked (21?23), but the 
occurrence of leukemia in five patients in the trials has emphasized that 
insertional mutagenesis and its oncogenic consequence is an unexpectedly 
frequent adverse effect of gamma?retroviral gene transfer technology.   
The discovery of the X?SCID disease gene has led to increased appreciation of 
the immunologic characteristics of this form of SCID and elucidation of 
molecular responses of lymphocytes to cytokines. 
 
§1.1 Biology of the γc transducing element 
IL?2RG encodes the γc of the IL?2 receptor.  The γc gene, localized to 
chromosome Xq13, encodes a transmembrane protein which is a transducing 
element shared by the cytokine receptor superfamily (2, 24).   
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The cytokine receptors are classified into five families on the bases of extra? 
and intra?cellular domains structure affinity: the cytokine receptor superfamily, 
interferon receptor family, tumor necrosis factor (TNF) receptor family, tumor 
growth factor (TGF)?β receptor family and IL?8 receptor family (25).  The 
cytokine receptor superfamily is the largest family, in which the receptors for IL?
6, IL?11, oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and leukemia 
inhibitory factor (LIF) contain the common gp130 (26, 27), the receptors for IL?3, 
IL?5 and granulocyte?macrophage colony?stimulating factor (GM?CSF) share the 
common beta subunit (28), whereas the receptors for IL?2, IL?4, IL?7, IL?9, IL?15, 
IL?21 and GH?R share the common γc element (25). 
The γc is expressed in lymphocytes and also in other cell types.  It is now clear 
that γc cytokines regulate several aspects of immune activation; they play an 
important role in supporting survival, proliferation and effector functions of 
activated immune cells.  Clearly, regulation of cell survival and cell apoptosis is a 
delicate teamwork and a balanced act of all γc?dependent cytokines is of central 
importance (Figure 2) (29). 
 
Figure 2. The γc dependent cytokines 
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The biological effects of cytokines are mediated through interaction with 
specific receptors, this leads to phosphorylation of intracellular proteins.  
Members of the cytokine receptor superfamily do not have intrinsic kinase 
activity, but recruit intracellular protein kinases following interaction with their 
ligands (30).  The tyrosine kinases that couple extracellular cytokine binding to 
intracellular phosphorylation of protein substrates, and eventually to cell growth 
and differentiation, are members of the Janus?associated kinase (JAK) family.  
Thus far, four distinct members of the JAK family are known in humans: JAK1, 
JAK2, JAK3 and Tyk2. 
Members of the IL?2R superfamily physically are associated with JAK1 and 
JAK3 (31, 32).  In the IL?2R, JAK1 interacts with the serine region of the β 
subunit, whereas the 48 C?terminal residues of the γc are required to bind JAK3.  
Both regions of the IL?2R chains are critical for JAK activation and signal 
transduction.  Following cytokine?cytokine receptor interaction and dimerization 
of the cytoplasmic tails of the cytokine receptor chains, the JAKs are brought into 
close proximity and may cross?phosphorylate each other.  Several signaling 
pathways are elicited by JAK1/JAK3 activation in members of the cytokine 
receptor superfamily (33).   
First, the phosphorylated cytokine receptor may associate with the adaptor 
SHC, which is itself phosphorylated and binds to Grb2.  Grb2 may thus anchor to 
Sos, the Ras guanine nucleotide exchanging factor.  Membrane translocation of 
the Grb2/Sos complex catalyzes the conversion of inactive, GDP?bound Ras to the 
active GTP?bound state and results in the activation of Raf?1 mitogen?activated 
protein kinase (MAPK) and eventually in the induction of immediate?early genes 
(c?fos, c?jun) (34).   
Second, JAKs may bind and phosphorylate insulin receptor substrates (IRSs).  
JAK activation by γc dependent cytokines results in phosphorylation of IRS?1, 
whereas evidence of JAK?dependent tyrosine phosphorylation of IRS?2/4 has so 
far been obtained only for IL?2, IL?4, IL?7 and IL?15 (35).  Once activated, IRS 
may bind the SH2 domain of the p85 subunit of phosphatidylinositol?3?kinase 
(PI3K) and the catalytic activity of the p 110 subunit of PI3K is eventually 
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elicited.  In addition to promoting PI3K activation, IRS may recruit Grb2 and thus 
amplify the Ras/raf?1 signaling pathway (36?38). 
A third essential event of the JAK signaling pathway is the phosphorylation of 
the class of transcription factors known as signal transducers and activators of 
transcription (STATs) (39).  The STATs factors comprise a diverse group of 
cytoplasmic proteins that are involved in several functions, such as regulation of 
the expression of effector genes, cell differentiation, survival and apoptosis (40).  
So far, seven mammalian STATs: STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6 have been characterized (40).  The STATs contain a tyrosine 
residue that may undergo JAK?mediated phosphorylation and they also contain 
SH2 and SH3 domains.  Following cytokine interaction with receptor and 
triggering of the JAK?mediated signaling pathway, STATs may interact with the 
cytokine receptor complex by binding via their SH2 domain to the 
phosphotyrosine of the cytokine receptor chain.  In addition, following STATs 
phosphorylation, STAT?STAT homo? or heterodimerization occurs, with the SH2 
domain of one STAT molecule binding to the phosphotyrosine of the second 
STAT.  The specificity of the response to cytokines is largely dependent on the 
particular combination of STATs recruited by the different signal?transducing 
chains of the cytokine receptor.  The differences in the STATs binding residues of 
the various cytokine receptors result in recruitment of specific STATs.  However, 
three crucial lymphocyte growth factors, IL?2, IL?7 and IL?15 activate STAT3 and 
STAT5 (41). 
Following dimerization, STATs translocate into the nucleus, where they bind 
to consensus sequences in the enhancer elements of the promoter regions of target 
genes and favor gene transcription (Figure 3).   
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Figure 3. The γc signaling transduction 
 
A potential role of γc in GH?R signaling has been proposed on the basis of the 
impairment of various GH?induced events in γc deficient conditions.  First, the 
signal transduction properties of GH?R in B?cell lines from X?SCID patients, 
following GH stimulation, is abnormal, in that GH stimulation fails to induce 
phosphorylation on tyrosine residues of several proteins, including STAT5 
molecule (42).  Previously, it has been reported on a patient affected with X?
SCID, short stature and peripheral GH hyporesponsiveness, an abnormal protein 
phosphorylation that normally occur following GH?R stimulation (43).  Of note, 
in this patient the immunological reconstitution through bone marrow 
transplantation paralleled the restoring of GH?R functionality, which resulted in a 
normal production of insuline growth factor I (IGF?I) (44).  GH is an important 
regulator of somatic growth, cellular metabolism, fertility and immune function.  
The GH?R was the first member of the cytokine receptor superfamily to be 
cloned (45).  Similarly to other members of the cytokine receptor superfamily, it 
consists of a transmembrane protein that contains two motifs and an extracellular 
domain (46).  GH?R lacks intrinsic kinase activity and signal transduction is 
mediated by receptor?associated cytoplasmic tyrosine kinases.  A prominent role 
is played by the JAK2 that associates to the GH?R cytoplasmic domain (47).  
After phosphorylation of JAK2, the receptor itself and several intracytoplasmic 
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molecules are promptly phosphorylated on tyrosine residues.  Further signaling 
proteins recruited to GH?R/JAK2 complex and/or activated in response to GH 
include: Shc proteins that presumably lead to the activation of MAPK pathway 
(48), insulin receptor substrates that has been implicated in the activation of PI3K 
and the kinase AKT/protein kinase (PK) B (49, 50), phospholipases that lead to 
formation of diacylglycerol and activation of PKC and a variety of proteins that 
are involved in the regulation of the cytoskeleton, including focal adhesion kinase, 
paxillin, tensin, CrkII, c?Src, c?Fyn, c?Cbl and Nck (51, 52).  This process 
ultimately results in the activation of STAT family members.  STATs proteins 
dimerize and translocate into the nucleus, where they bind to specific DNA 
responsive elements of GH target genes, eventually inducing the activation of 
gene transcript (53).  The duration of GH?activated signals is a key factor in 
relationship to the biological actions of the hormone.  Removal of cell surface 
GH?R by endocytosis is an early step in the termination of GH?dependent 
signaling (54).  Furthermore, suppressors of cytokine signaling (SOCS) proteins 
act as negative regulators of the JAK/STAT signal cascade (55).  Moreover, 
several studies documented that there are at least three different phosphatases 
involved in the specific down?regulation of GH?R signaling: SH2 domain?
containing protein?tyrosine phosphatase (SHP)?1, tyrosine?protein phosphatase 
(PTP)?1B and PTP?H1 (40).   
Thus, it is clear that STAT5 proteins, in particular, are strongly correlated with 
some oncogenic events, such as proliferation and apoptosis (56); so, the 
therapeutic inhibition of these transcription factors may be proven helpful for 
those diseases characterized by an alteration of cell growth homeostasis.  
Moreover, the development of selective inhibitors of STAT activation may be a 
promising area in the field of novel anticancer therapeutics (57).   
It remains to be further elucidated whether the γc involvement is required for 
the expression of the biologic effects of GH and its intermediate molecules on cell 
growth in either physiological or pathogenic conditions.  
These data have been published as Review on Cellular Immunology, for the 
manuscript see below. 
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§1.2 The γc provides spontaneous or induced cell proliferation 
The intrinsic property of γc in cell cycle progression has been long debated.  In 
fact, although gene therapy trials have been proved as a beneficial alternative 
approach to cure X?SCID patients carrying mutations of γc, a malignant 
lymphoproliferation occurred in 5 out of 20 patients enrolled into the two different 
trials (20, 58), not observed in gene therapy trials for SCID due to ADA 
deficiency (59).  To explain these adverse events, studies were conducted to 
define whether the retroviral insertional mutagenesis could have played a role.  In 
4 cases an aberrant transcription and expression of LMO2 was clearly documented 
(60).  Even though the other patients may have the vector integration near LMO2 
or other oncogenes (60), it is also conceivable that the transgene could have a role 
per se in cell cycle progression.  Of note, development of leukemia, similar to 
other cancers, requires multiple genetic changes caused by a diverse group of 
genes that inhibit apoptosis and/or provide growth advantage to the leukemic cells 
(61).  In keeping with this hypothesis, overexpression of γc transduced through a 
lentiviral vector into stem cells in murine model of X?SCID led to T?cell 
lymphomas and thymic hyperplasia in a third of the cases.  Intriguingly, no 
common integration site was found between the mice, which developed T?cell 
lymphomas (62).  In these mice, differently from humans treated with gene 
therapy for X?SCID, the expression levels of the protein was elevated, thus 
implying that the amount of the protein may be crucial for the γc control of cell 
cycle (63).  These results suggest that insertional mutagenesis may not be the only 
cause of laeukemogenesis and that the expression levels of γc could influence the 
cell cycle progression directly or its effect being mediated by cytokines triggers.  
It has been documented that γc receptors activity enhances leukemogenesis 
(64).  To define an intrinsic mitogenic property of γc dependent on the amount of 
the protein, we used in vitro cellular models containing different amounts of γc.  
In particular, EBV?transformed B?cells (BCLs) from normal subjects, cells 
transduced with lipid vector containing nontargeting short interfering RNA 
(siRNA), BCLs transduced with siRNA to knockdown γc expression and BCLs 
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from X?SCID patients were used.  Our results indicate that silencing of γc induces 
a substantial decrease of protein amount in BCLs, which allowed us to 
demonstrate a direct involvement of γc in self?sufficient growth of BCLs in a 
concentration dependent manner.  We, also, found that the amount of 
constitutively activated JAK3 parallels the extent of γc expression.  This finding is 
intriguing, in that constitutively active or hyperactive JAK proteins have crucial 
roles in hematopoietic malignancies, by promoting oncogenic transformation (64).  
In particular, JAK overexpression can be considered as one of the main biologic 
events leading to the constitutive activation of the JAK/STAT pathway that 
contributes to oncogenesis (65).  In lymphoid cells, the involvement of the 
JAK/STAT pathway in several cellular processes, such as proliferation and 
protection from apoptosis, has also been well documented (66, 67).   
We found that γc silencing also inhibits GH?induced cell proliferation.  In this 
context, it is known that the activation of JAKs and STATs represents a prominent 
biochemical event during GH?dependent proliferation of lymphoid cell lines (57, 
68?71) and STAT5 is considered a transforming agent in lymphoma and other cell 
types (72), therefore we found that the reduction of γc amount also inhibits 
STAT5 activation and its subsequent nuclear translocation, which follows GHR 
perturbation.  Of note, it should be mentioned that experimental studies document 
a role for GH in the initiation and/or promotion of tumorigenesis, raising the 
possibility that patients treated with GH might be at increased risk of cancer (73).  
Moreover, a putative role of GH as a cofactor in tumor growth is plausible, since 
several carcinomas express GHR (74).  In animal models, GH increase the 
incidence of leukemia and solid tumors, and in humans, at supraphysiological 
doses, it can promote lymphoproliferative events (75).   
In conclusion, our data demonstrate a direct relationship between the amount of 
γc expression and its role in cell cycle progression.  These data add new evidence 
for a possible intrinsic mitogenic role of γc related to its cellular amount.  This 
biologic effect could be direct, thus related to the molecule per se, or indirect and 
mediated by the participation to cytokine?receptors signaling.  Therefore, since 
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results of gene therapy trials for X?SCID have been very promising, to achieve 
safer results, the modulation of the transgene expression could help reduce the 
risk of undesirable events.   
These data have been published as Article on The Journal of Immunology, for 
the manuscript see below. 
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§1.3 Role of γc on spontaneous cell cycle progression in malignant cell lines 
Cell cycle progression is a highly organized and regulated process that controls 
cell proliferation (76).  Cytokines that signal through receptors sharing the γc lead 
to transition into the cell cycle and thus proliferation (77).  The entry of cells into 
the cell cycle is controlled by an ordered expression/activation of cyclins (78).  
IL?2R through γc appears to activate a variety of downstream signaling pathways 
that converge on the regulation of Bcl?2 (79), including PI3K and MAPK 
activation (29) and transcription of the c?myc gene (79).  In turn, c?myc cooperates 
with STAT5 to induce the expression of cyclin D and to promote proliferation 
(80?82).  It is clear that alterations in Bcl?2 family members levels exert potent 
effects on cellular survival and, namely, Bcl?2 overexpression can be tumorigenic 
(83).  Moreover, γc is required for a wide range of signaling inputs that induce cell 
proliferation through cyclin D3 expression (84). 
To determine whether γc deficiency had an effect on cell survival we examined 
BCLs from healthy donors and X?SCID patients.  The percentage of live cells was 
determined using trypan blue staining in the absence or presence of anti?Fas to 
trigger programmed cell death.  In unstimulated X?SCID BCLs there was an 
increase in the percentage of cell death.  Following stimulation with anti?Fas, 
control and X?SCID BCLs showed a higher and comparable degree of cell death 
(Figure 4A).  Programmed cell death is mainly mediated by activation of several 
caspases (85).  These molecules exist as pro?forms that are activated by cleavage 
by the upstream caspase in the cascade (85).  In unstimulated X?SCID BCLs the 
low viability was not a caspase?dependent process, since the presence of the 
cleaved protein was observed only following anti?Fas stimulation (Figure 4B).  
Caspase?independent cell death has been attributed to mitochondrial damage (86), 
which can be regulated by Bcl?2 family members (87, 88).  Bcl?2 and Bcl?XL 
operate as critical components in a complex network to integrate information and 
make ultimate life?death decisions.  Since the γc?dependent cytokines promote cell 
survival by up?regulating the antiapoptotic factor Bcl?2 (89) and Bcl?XL (90), the 
expression of Bcl?2 and Bcl?XL in control and X?SCID BCLs was evaluated.  In 
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γc?deﬁcient cells, the expression of Bcl?2 and Bcl?XL was greatly decreased as 
compared with the control (Figure 4B).  These findings indicate that γc is 
required for cell survival and is dispensable for Fas induced cell death.  Moreover, 
the evaluation of molecular expression of Bcl?XL in unstimulated cells through 
quantitative real?time PCR, revealed that in the X?SCID cells, Bcl?XL mRNA was 
35% of the control (Figure 4C).  However, evidence exists that autophagy can 
plays an active role in cell death, by contributing to cell death in unfavourable 
settings such as nutrient or growth factors deprivation (91).  In keeping with this, 
probably γc could have a role in the autophagy process.  
 
    
Figure 4. Deficiency in the expression of γc has effect on cell survival.  (A) BCLs were 
cultured in the absence or presence of 400 ng/ml anti?Fas for 6 hours.  The percentage of cell death 
was evaluated through trypan blue staining.  Filled bars indicate BCLs from X?SCID patients; 
open bars BCLs from healthy donors (CTR).  Data are expressed as mean (± SD) of 6 experiments.  
(B) BCLs were either cultured in medium alone or stimulated with anti?Fas.  After 6 hours, whole 
cell extracts were prepared, caspase?3, Bcl?2 and Bcl?XL expression was determined by Western 
blotting.  (C) mRNAs extracted from unstimulated cells were reverse?transcribed and analyzed for 
the expression of Bcl?XL by qRT?PCR.  Data were normalized to beta?actin. 
 
To define whether the effect of γc on cell cycle progression is a peculiarity of 
lymphoblastoid cells or a more general phenomenon involved in cell growth of 
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malignancies of hematopoietic cell lineages, in this study we evaluated whether γc 
expression could interfere in cell cycle progression in neoplastic cells.  We first 
examined the expression of the molecule in cell lines obtained from hematopoietic 
tumors, such as Molt?4, Raji, Rj225 and K?562.  The protein was expressed 
predominantly in the K?562 and to a lesser extent in the Molt?4, Raji and Rj225 in 
a decreasing order.  In X?SCID BCLs, γc expression was completely undetectable.  
The expression of γc was also evaluated in primary leukemic samples from 
patients with ALL through quantitative real?time PCR.  IL?2Rγ mRNA levels was 
greatly increased in leukemic cells as compared with the control (Figure 5). 
     
Figure 5. Different γc expression levels in malignant cell lines.  (A) X?SCID BCLs, Burkitt 
lymphoma cell line (Raji), the chronic myelogenous leukemia cell line (K?562), the human T?acute 
lymphoblastic leukemia cell line (Molt?4) and Raji isogenic derivative (Rj225) were lysed and 
immunoblotted for γc and beta?actin, as a loading control.  (B) Densitometric analysis of the above 
Western blot.  ImageJ program was used to generate the data.  Data are representative of 6 distinct 
experiments.  (C) Primary leukemic cell lines, consisting of acute lymphoblastic leukemia (ALL) 
cells, and control cells were analyzed for the γc expression by qRT?PCR.  Histogram shows the 
relative gene expression as IL?2Rγ/actin fold increase.   
 
Moreover, to determine whether the expression levels of γc correlated with the 
self?sufficient growth in malignant cell lines, we examined the proliferation 
activity of cells under serum?deficient conditions.  This was first evaluated by 
comparing the CFSE dilution profile, upon trypan blue exclusion assay, of 
malignant cells.  After 5 hours of serum?free culture some variations in the rate of 
proliferation among the lines were already evident.  K?562 had a high 
proliferation rate, compared with the other cell lines.  No proliferation was 
observed in X?SCID BCLs (Figure 6A?C).  Moreover, the proliferation of these 
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cell lines was also assessed by 3H?thymidine incorporation assay.  The data were 
in keeping with the results of CFSE experiments.  A statistically significant 
relationship between γc expression and spontaneous cell growth was documented 
in the examined cell lines (R = 0.98, p < 0.05) (Figure 6D). 
 
Figure 6. Relationship between γc expression and spontaneous cell growth in malignant cell 
lines.  (A) X?SCID BCLs, Raji, K?562, Molt?4 and Rj225 were cultured in the absence of serum 
and stained with 1.7 ?M CFSE.  After 6 hours of culture, cells were analyzed by flow cytometry.  
Histograms show CFSE profiles 6 hours following the start of culture.  Solid black peaks represent 
the start of the culture. (B) Percentages of CFSE positive cells were obtained in the indicated cell 
lines by flow cytometry.  Graphical representation of the mean (± SD) of percentage of CFSE 
positive cells for the 3 experiments conducted.  (C) After starvation, X?SCID BCLs, Rj225, K?562, 
Molt?4 and Raji were cultured in serum?free medium for 4 days and pulsed with 0.5 ?Ci 3H?
thymidine for 8 hours.  Data represent mean (± SD) of 6 experiments.  (D) Correlation between 
thymidine incorporation and γc expression in malignant cells.  A positive correlation was 
demonstrated by the Pearson correlation coefficient (R = 0.98, p < 0.05). 
 
In the light of these findings, we hypothesized that the inhibition of γc 
expression in hematopoietic malignant cell lines might have a direct effect on 
proliferation of these cells.  Short interfering RNA (siRNA) was used to 
knockdown the molecule in these cell lines.  Efficiency and specificity of targeted 
siRNA sequences were confirmed by western blot analysis on total lysates and 
quantitative real?time PCR on mRNA.  As shown in Figure 4A?B, the results of 
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western blot assay revealed that at 96 hours following the transfection, cells 
transduced with siRΝΑ had less γc protein than the correspondent cells transduced 
with the control negative siRNA.  In this representative experiment, γc?silencing 
reduced the amount of the protein in Rj225, K?562, Molt?4 and Raji by 80, 53, 62 
and 32%, respectively.  In addition, a decrease of the IL?2Rγ mRNA was observed 
in all cell lines, revealing a knockdown efficiency of approximately 85%.  In X?
SCID cells, IL?2Rγ mRNA was undetectable (Figure 7A?C).  Moreover, γc 
knockdown led to a signiﬁcant decrease of proliferation.  In particular, γc?
silencing reduced cell proliferation of Rj225 by 40%, K?562 by 58%, Molt?4 by 
45% and Raji by 50%, as compared with control siRNA cells (Figure 7D).  Taken 
together, these data confirm that γc plays a key role in the proliferation of these 
malignant cell lines.  
 
Figure 7. Effect of γc siRNA transfection on the expression level of protein and cell 
proliferation of malignant cell lines.  (A) Western blot analysis of γc and beta?actin protein 
expression in Rj225, K?562, Molt?4 and Raji transfected with γc siRNA or  transfected with 
negative control siRNA after 96 hours of transfection.  (B) Densitometric analysis of the above 
Western blot.  ImageJ program was used to generate the data.  Data were equalized for the 
background. Results are representative of 5 distinct experiments.  (C) IL?2Rγ mRNA transcript 
evaluated by quantitative real?time PCR.  Relative mRNA expression was determined using beta?
actin control. (D) The proliferation of Rj225, K?562, Molt?4 and Raji transfected with γc siRNA or 
transfected with negative control siRNA was evaluated through 3H?thymidine incorporation assay.  
Data represent mean (± SD) of 5 distinct experiments.  
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Alterations in cell cycle machinery, mainly in the regulation of G1/S phase, are 
known to be associated with the development of solid tumors as well as 
hematological malignant diseases (92).  To examine the mechanisms by which γc 
regulates cell cycle progression, we examined whether different amounts of the 
molecule were able to influence the transcription of genes selectively involved in 
cell cycle.  Of note, cyclins are the key regulators of cell cycle progression (78).  
In particular, during the G0 to G1 phase transition, cyclins D1, D2 and D3 are the 
first molecules to be induced.  Cyclin A2 gets activated during the transition from 
G1 to S phase and B type cyclins are detected during G2 exit and mitosis phase 
(93).  Namely, cyclins A2 and B1 have been implicated in the pathogenesis of 
cancer and are overexpressed in several tumors (94, 95).  Evidence indicates that 
these cyclins are key components of the cell?cycle machinery (96) and, in 
particular, cyclin A is expressed at high levels in hematopoietic stem cells and is 
essential for their proliferation (97).  In our study, we observed that the expression 
of A2 and B1 cyclins strongly paralleled the proliferative capability of malignant 
cell lines (Figure 8B).  Interestingly, a positive correlation between the amount of 
γc and the expression of cyclins A2 and B1 was also found (Figure 8C, D).  
Taken together these data indicate that the higher is the rate proliferation of a 
certain cell line the higher is the expression of both γc and cyclins A2 and B1, 
thus confirming their involvement in the process in a concentration dependent 
fashion.  We also found an increased expression of all D?type cyclins in those cell 
lines that proliferated mostly, K?562 and Molt?4, whereas they were not expressed 
in the other cell lines, but D1 found in Rj225 (Figure 8A).  
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Figure 8. Cyclins expression is upregulated in malignant cell lines.  (A?B) RNAs extracted and 
reverse?transcribed were analyzed for the expression of D1, D2, D3 and A2, B1 cyclins by qRT?
PCR.  Histograms show the relative gene expression as cyclin/actin fold increase.  Relative 
expression of cyclins were calculated for each cell line after normalizing against beta?actin. (C) 
Correlation between γc protein amount, expressed as relative density, and fold increase cyclin 
B1/actin expression.  (D) Correlation between γc protein amount, expressed as relative density, 
and fold increase cyclin A2/actin expression.   
 
D?type cyclins are strongly expressed in many malignancies.  Overexpression 
of cyclin D1 protein was documented in many forms of cancer, including breast 
cancer (98), while overexpression of cyclin D2 was noted in a wide range of B 
cell malignancies, such as B cell chronic lymphocytic leukemia (99).  Like the 
other D cyclins, cyclin D3 is rearranged and the protein is overexpressed in 
several human lymphoid malignancies.  It was documented that knockdown of 
cyclin D3 inhibits the proliferation of acute lymphoblastic leukemia cells (100).  
However, while A and B type cyclins seem to be vital and necessary components 
of cell cycle progression (97), D?type cyclins may be dispensable for proliferation 
under certain circumstances, in that different cell types are sensitive to cyclin D 
knockdown at a different extent (101).  This would suggest that they regulate cell 
cycle in a cell?type specific manner and that there are alternative mechanisms 
 ??
allowing cell cycle progression in a cyclin D?independent fashion (101).  
Anyway, a critical role for oncogenic transformation of D?type cyclins is a well 
established feature.  
 
§1.4 Conclusive remarks 
It’s noteworthy that immune and endocrine systems participate to an integrated 
network of soluble mediators that communicate and coordinate responsive cells to 
achieve effector functions in an appropriate fashion (102).  There is evidence 
documenting that immune cells express GH?R (42).  It has also recently been 
shown a novel dependence of GH signaling on the γc cytokines receptor in certain 
cell types, suggesting the interplay between endocrine and immune system (42).  
GH?R can promote cell cycle progression of lymphoid cells and of a wide variety 
of other cells.  Indeed, we documented a direct involvement of γc in self?sufficient 
growth and GH induced proliferation in a concentration dependent manner of the 
molecule (103).  GH?R signaling apparatus also involves potent mitogenic 
molecules such as STATs that play a role in cell proliferation (104).  Moreover, it 
was previously reported that IL?2RG cooperates with LMO2 in inducing 
hematopoietic tumors by studies of insertional mutagenesis in mice (105), thus 
giving a potential explanation to lymphoproliferative disorders occurring during 
gene therapy trials for X?SCID (106, 107).  It is noteworthy that, differently from 
X?SCID, no clonal lymphoproliferation has been reported, to date, in patients 
receiving gene therapy for ADA deficiency (108), despite the observation of a 
similar frequency of integration sites near LMO2 and other proto?oncogenes 
(109).  Furthermore, a recent study, based on an experimental model of gene 
transfer in γc?/? mice, documented that γc overexpression could exert oncogenic 
properties by itself (110). 
Moreover, our data indicate that γc is strongly implicated in cell cycle 
progression of hematopoietic malignancies in a similar fashion to the role played 
in control lymphoblastoid cells, as previously shown.  This biologic effect is 
strictly dependent on the expression level of the molecule and can be abolished by 
gene knockdown.  Of note, a direct correlation between the amount of γc 
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expression and the proliferative capability of the malignant cell lines and the 
regulatory elements of cell cycle progression, A and B cyclins, was found.   
Our data could provide the basis to develop in the near future new therapeutic 
strategies targeting this molecule in cancer therapy.  Moreover, this information 
may also help understand undesired side effects of gene therapy trials. 
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CHAPTER II 
“Nude/SCID syndrome due to alterations in FOXN1” 
 
In humans, the thymus which is the only organ capable to support the 
differentiation and selection of mature T lymphocytes (111).  The prenatal thymus 
development, the maintenance of a proper thymic microenviroment and the 
efficient T?cell production require an appropriate crass?talk between thymocytes 
and thymic stromal cells (112).  The postnatal thymic involution results in 
dramatically reduced T?cell generation in an age?dependent manner (113).  The 
thymic stromal compartment consists of several cell types that collectively enable 
the attraction, survival, expansion, migration and differentiation of T?cell 
precursors.  The thymic epithelial cells (TECs) constitute the most abundant cell 
type of the thymic microenvironment and can be differentiated into 
morphologically, phenotypically and functionally separate subpopulations of the 
thymus (114).  The Foxn1 gene is expressed in skin epithelial cells, hair follicles 
and TECs.  Foxn1 function, as a transcriptional activator, is absolutely required 
for the normal differentiation of hair follicles and TEC (115).  Foxn1 encodes a 
transcription factor whose function is essential for subsequent epithelial 
differentiation; without it, colonization of the anlage by thymocyte progenitors 
fails (116) and thymopoiesis is aborted, resulting in severe immunodeficiency 
(117).  In fact, both mice and humans mutations in Foxn1 gene resulting in a 
complete absence of the protein, display the ‘nude’ phenotype, which is 
characterized by hairlessness and congenital athymia.     
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§2.1 T?cell development and Thymus 
The thymus is the primary lymphoid organ that supports T cell differentiation and 
repertoire selection (118, 119).  The intrathymic development of T cells consists 
of several phases that require a dynamic relocation of developing lymphocytes 
within multiple architectural structures of this organ.  Following the entry into the 
thymus through the cortico?medullary junction, lymphoid progenitor cells begin 
their commitment toward the T?cell lineage.  The developmental pathway is 
traditionally divided into three subsequent steps, as defined by peculiar 
immunophenotypic patterns: the CD4–CD8– double negative (DN) stage, the 
CD4+CD8+ double positive (DP) stage and the CD4–CD8+ or CD4+CD8– single 
positive (SP) stage.  In mice, an immature single positive (ISP) CD8+CD4– cell 
may be detected between the DN and DP stages (Figure 9).     
 
Figure 9. Steps of the T?cell development 
 
DN cells in mice can be further subdivided based on the expression of CD44 
and CD25 in the following populations: CD44+CD25– (DN1), CD44+CD25+ 
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(DN2), CD44–CD25+ (DN?) and CD44–CD25– (DN4) (120).  The immature 
thymocytes journey through the thymus has also the additional effect of 
promoting the differentiation of thymic stromal precursors into mature TECs, thus 
playing an important role in the formation of the thymic microenvironment (121?
124).  In particular, thymocytes during the DN1?DN3 stages participate to the 
differentiation process of TEC precursor cells into cortical TECs (cTECs).  The 
DN2 to DN3 stage transition requires the expression of a different arrays of genes, 
as the induction of recombinase activating gene?1 (RAG?1) and RAG?2, the 
upregulation of pre?Tα (pTα) and the rearrangement of TCRδ and γ.  These cells 
become competent to undergo β?selection and express the pre?TCR complex on 
their surface and reach the DN3 stage (125).  After β?selection, the thymocytes, 
which have properly rearranged TCRβ chains, show a burst of proliferation and a 
subsequent upregulation of CD8 and then CD4 and become DP cells.  Eventually, 
DP cells rearrange TCRα gene, leading to TCRα assembly into a TCR complex.  
In the cortex, the DP thymocytes interact through their TCR with peptide?MHC 
complexes expressed by stromal cells, as cTECs and dendritic cells (126).  At this 
site, take place the positive selection, where ‘productive’ T cells react to foreign 
antigens, but not to self antigens (111).  Lately, positively selected DP thymocytes 
are ready to differentiate into SP cells, that is CD4+CD8– or CD4–CD8+ and 
relocate into the medulla.  At this site, newly generated SP thymocytes are further 
selected by the medullary stromal cells, including autoimmune regulator (AIRE)?
expressing mTECs.  The cells that are reactive to tissue?specific self antigens are 
deleted, thus avoiding autoimmunity (111).  SP thymocytes egress from the 
thymus as recent thymic emigrants (RTE), naïve cells expressing the CD62 ligand 
(CD62L), also known as lymphocyte (L)?selectin, CD69 and the CD45RA 
isoform.  These RTE cells are fully mature T cells that exert proper functional 
capabilities of cell?mediated immunity (127?129). 
 
§2.2 The clinical spectrum of the Nude/SCID phenotype  
In 1966, Flanagan identified a new mouse phenotype characterized by loss of the 
hair.  This mouse showed an abnormal keratinization in hair fibers, with follicular 
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infundibulum unable to enter the epidermis (130).  These affected mice also 
showed an inborn dysgenesis of the thymus (131) resulting in a compromised 
immune system lacking T cells (Figure 10).  The mouse ʽnudeʼ phenotype results 
from inactivating mutations in a single gene, originally named winged?helix?nude 
(whn), recently known as forkhead box n1 (foxn1)(132). 
Mice homozygous for the mutation ʽnudeʼ are hairless have retarded growth, 
decreased fertility and die by 5 months of life for infections (130).  The thymus is 
absent at birth (133) and there are very few lymphocytes in the thymus dependent 
areas of the spleen and lymph nodes (134).  Since the abnormal, or even absent, 
thymus is the hallmark of the ʽnudeʼ phenotype, these animals develop a profound 
T?cell deficiency and a severely impaired immune response of either cell?mediated 
and, indirectly, humoral immunity.  ʽNudeʼ mice show lymphopenia and also low 
immunoglobulin levels.  In the absence of normal T cells originated from the 
thymus, the development of the antibody forming cells is delayed, although 
ʽnudeʼ mice do not lack precursors of antibody forming cells.  This indicated that 
antibody forming cells can mature in the absence of the thymus, although at a 
slower rate (135).  In ʽnudeʼ mice lymph nodes, the outer cortex with primary 
nodules and the medullary cords are normal.  In the spleen sections from the 
ʽnudeʼ mice, the proportion of red to white pulp is greater than normal and, in 
some cases, an unusually high number of megakaryocytes are seen in the red pulp.  
In some spleens, Malpighian follicles, although present, are fewer and smaller 
than in controls and a depletion of lymphocytes is constant in the close proximity 
of the central arteriole in the thymus?dependent area.  The depletion in the splenic 
thymus?dependent areas is not as prominent as in the lymph nodes (134).   
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Figure 10. ʽNudeʼ mouse phenotype 
 
For many years the human counterpart of ʽnudeʼ mouse phenotype has been 
erroneously considered the DiGeorge syndrome that occurs spontaneously and is 
mainly characterized by thymic hypoplasia or aplasia.  Children with DiGeorge 
syndrome also have lymphopenia, with a reduction of T cells that are poorly 
responsive to common mitogens (136).  
The discovery of the human phenotype completely equivalent to the ʽnudeʼ 
mouse phenotype began with the identification of two sisters, whose clinical 
phenotype was characterized by congenital alopecia, eyebrows, eyelashes, nail 
dystrophy and several T?cell immunodeficiency (18).  The two patients were born 
from consanguineous parents who originated from a small community of south of 
Italy that may be considered geographically and genetically isolated.  This led to 
consider the syndrome as inherited as an autosomal recessive disorder.  The T?cell 
defect was characterized by a severe functional impairment, as shown by the lack 
of proliferative response to common mitogens. 
Due to the similarities between the human clinical features and the ʽnudeʼ 
mouse phenotype, a molecular analysis of the FOXN1 gene was performed in 
these patients and revealed the presence of a C?to?T shift at 792 nucleotide 
position in the cDNA sequence.  This mutation leads to a nonsense mutation 
R255X in exon 5 with a complete absence of a functional protein (19), similar to 
the previously described rat and mouse Foxn1 mutations.  In humans, FOXN1 is 
located on chromosome 17 (in mice, chromosome 11). 
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Later, the identification of the haplotype for the FOXN1 locus, by analysing 47 
chromosomes carrying the mutation R255X, led to identify the single ancestral 
event that underlies the human Nude/SCID phenotype.  As this form of SCID is 
severe due to the absence of the thymus and the blockage of T?cell development, a 
screening program for prenatal diagnosis in this population was conducted for the 
identification of fetuses carrying the mutation.   
Interestingly, additional studies have also reported on anomalies of brain 
structures, suggesting of a potential role of FOXN1 in brain embryogenesis, as 
also suggested by its expression in epithelial cells of the developing choroids 
plexus in mice, a structure filling the lateral, third and fourth ventricles.  However, 
the severe neural tube defects, including anencephaly and spina bifida, have been 
only inconstantly reported, thus probably indicating that the genetic alteration 
represents a cofactor and is not sufficient per se to alter brain embryogenesis (137, 
138).  
A report on an athymic Nude/SCID fetus gave us the unique opportunity to 
gain further insights into the prenatal ontogeny of T lymphocytes in humans.  
Since under certain circumstances, such as immunodeficiencies (139), maternal 
cells may cross the placenta and engraft into the fetus in utero, all samples were 
analyzed after exclusion of maternal cell contamination, by evaluating 15 highly 
polymorphic autosomal short tandem repeat loci through multiplex?PCR (Figure 
11).  
  
Figure 11. A representative electropherogram.  Four short?tandem?repeat (D19S433, vWA, 
TPOX, D18S51) useful to exclude maternal contamination.  Numbers denote allelic designations 
of individual loci. 
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The immunological and molecular events have been analyzed, with a particular 
attention to the expression of developmentally regulated markers of T?cell 
ontogeny, such as those ones expressed by RTE, and to the study of the TCR 
repertoire.  Our results provide an evidence on the crucial role of FOXN1 in the 
early prenatal stages of T?cell ontogeny in humans, in that its alteration leads to a 
total blockage of CD4+ T?cell maturation and a severe impairment of CD8+ cells 
with an apparent bias toward γδ T?cell production (140).  
These data have been published as Article on Rivista Italiana di Genetica ed 
Immunologia Pediatrica, Journal of Neurological Science and Journal of Medical 
Genetics, for the manuscripts see below. 
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§2.3 Role of FOXN1 in Immune System  
A critical role of the FOX transcription factors in the development of different 
tissues has been shown in a number of studies where FOX genes have been 
inactivated by gene targeting or mutations (141).  These transcription factors share 
the common property of being developmentally regulated and of directing tissue 
specific transcription and cell fate decisions.   
In particular, FOXN1 gene, spanning about 30 kb (131, 142), is an epithelial 
cell?autonomous gene and is highly conserved in sequence and function in rodents 
and humans.  The molecular mechanisms by which FOXN1 expression and 
activity are regulated are only incompletely understood.  Wnt proteins and bone 
morphogenetic proteins (BMPs) have been implicated in the transcriptional 
control of FOXN1.  BMP4 has been shown to upregulate the expression of 
FOXN1, and FOXN1 might subsequently upregulate the expression of fibroblast 
growth factor (FGF) receptors (FGFRs), which in turn modulate the thymic 
stroma differentiation and thymopoiesis (143).  Wnt proteins expressed by TECs 
and developing thymocytes can induce the expression of FOXN1.  This seems to 
result from stabilization of β?catenin and it can be further regulated by PI3K 
through an undefined mechanism (Figure 12) (144).  In vitro exposure of TECs to 
some Wnt is sufficient to upregulate FOXN1 protein expression in both an 
endocrine and paracrine fashion (145).  Wnt belong to a large family of secreted 
glycoproteins that have important roles in cell?fate specification (143).  
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Figure 12. Thymic development and FOXN1 
 
Foxn1 is expressed in all TECs during initial thymus organogenesis and is 
required for the initial phase of their differentiation (117).  Foxn1 exerts an 
important role (146) in inducing both cortical and medullary differentiation (147, 
148).  Although FOXN1 has been long studied, most of the studies thus far 
available are restricted to fetal differentiation process, while its postnatal role in 
the mature thymus still remains to be fully elucidated. 
 
§2.4 Conclusive remarks 
Despite an extensive knowledge about the thymus role to foster T?cell 
development is available, some still unexplained evidence in human athymic 
conditions suggests that in?depth information of this process is still to be achieved 
and, in particular, the involvement of different non?lymphoid tissues in T?cell 
ontogeny.  In human Nude/SCID, the absence of thymic tissue results in a severe 
T?cell immunodeficiency.  Since FOXN1 is selectively expressed in the thymus 
and skin, skin epithelial cells could play a role for a productive T?cell ontogeny, 
as previously shown in in vitro models (149).  
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Our results demonstrate that FOXN1 is crucial for in utero T?cell development 
and not for B? and NK?cell differentiation in humans.  The identification of a 
limited number of CD8+ cells, bearing TCRγδ, suggests a different origin for these 
cells, which are however unable to sustain a productive immune response into the 
periphery.  Thus, the expression of this factor in other tissue can be replacing the 
putative pivotal role of the thymus in maturation of thymocytes. 
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CHAPTER III 
“Ataxia?Teleangiectasia due to alterations in ATM” 
 
Ataxia?telangiectasia (A?T) is a rare recessive neurodegenerative disease that 
results from mutations in the ATM gene, resulting in diminished amounts or 
absence of ATM protein and/or ATM kinase activity (150).  A?T is primarily a 
neurodegenerative disorder, whose underlying pathogenesis consists of a 
progressive cerebellar degeneration, mainly involving Purkinje and granule cells 
(151, 152).  Neuronal degeneration is characterized by widespread loss of 
Purkinje cells in the cerebellum, atrophy of the cerebellar folia, granule cell loss 
and significant thinning of the molecular layer as revealed by autoptic and bioptic 
studies (153).  Immunodeficiency is present in 60?80% of individuals with A?T, it 
is variable and do not correlate well with the frequency, severity or spectrum of 
infections (154, 155).  The immunodeficiency is progressive and the most 
consistent immunodeficiency reported is poor antibody response to pneumococcal 
polysaccharide vaccines (154).  Moreover, serum concentration of the 
immunoglobulins IgA, IgE and IgG2 may be reduced.  Approximately 30% of 
individuals with A?T who have immunodeficiency have T?cell deficiencies.   
Neither the normal function of ATM in the nervous system nor the biological 
basis of the degeneration in A?T has been extensively elucidated (150, 156).  
ATM is the central component of the signal?transduction pathway responding to 
DNA double?strand breaks (DSBs) caused by ionizing radiation, endogenous and 
exogenous DNA damage agents (157, 158).  Following ATM activation, several 
DNA?repair and cell cycle checkpoint proteins are activated, leading to cell cycle 
arrest and DNA repair (159, 160).  ATM plays a controlling role in recognition 
and repair of DNA damage, cell cycle arrest and cellular apoptosis by interacting 
with several downstream substrates (161).  Thus, this disease is considered the 
prototype of DNA?repair defect syndromes (162).  ATM is also involved in 
sensing and modulating intracellular redox status, even though it is not clear 
whether ATM is likely to prevent reactive oxygen species (ROS) production 
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(163).  As for the molecular mechanisms of action of betamethasone, several lines 
of evidence indicate that steroids have remarkable effects through both 
nongenomic and genomic mechanisms, the latter well documented also in neural 
system (164, 165).  The classical genomic mechanism of glucocorticoid action is 
cytoplasmic glucorticoid receptor (GR) mediated.  Glucorticoids (GCs) bind and 
induce GR activation, followed by the GR translocation to nucleus and subsequent 
binding to glucocorticoid responsive element (GRE), thus modulating the 
transcription of a variety of genes including glucocorticoid?induced leucine zipper 
(GILZ) (Figure 13).  GILZ is known as a marker GC transcriptional activity, 
rapidly induced by GC, able to regulate T lymphocytes activity, including T cell 
survival (166, 167).   
 
Figure 13. Glucorticoids response and GILZ signaling. 
 
Unfortunately, currently there is no effective treatment for A?T, but supportive 
care of neurological symptoms, as physical, occupational and speech/swallowing 
neurorehabilitation.  Eventually, the progressive neurodegeneration and 
pneumonia are a frequent cause of death in patients with A?T.  
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§3.1 Effects of steroid treatment in patients affected with Ataxia?
Telangiectasia 
?ven though A?T is a non?curable disease that leads to a progressive 
neurodegenerative phenotype, a recent clinical report documented a drug?
dependent improvement of neurological symptoms induced by a short course of 
oral betamethasone (168).  This beneficial effect was inversely correlated with the 
severity of cerebellar atrophy, which is age?dependent (169). 
We tried to determine the minimum?therapeutically?effective dosage of 
betamethasone, in order to reduce steroid?related side effects.  The effect was still 
appreciable at a dosage as low as 0.01 mg/kg/day, corresponding to 10% of the 
full dosage.  A long term study with low steroid dosage would also help define the 
benefit to risk ratio of such therapeutic intervention, to limit the concern on the 
immunosuppressive effect on the susceptibility to infections of these patients.  
Although this is an observational study on a limited number of affected patients, 
of note, in our study we found that GILZ expression in lymphocytes promptly 
increased in all patients during GC therapy at low dosage.  Even though there is 
no evidence to prove that betamethasone may act in the brain, nevertheless, a 
recent study revealed the GILZ is expressed in specific areas of the brain and is 
upregulated in several brain regions of stress?exposed mice (170).   
Our data indicate that betamethasone is effective in A?T at a minimal dosage 
and that GILZ may be a useful biomarker of the clinical response.   
This study has been published as Article on The European Journal of 
Neurology, for the manuscript see below.  
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§3.2 Conclusive remarks 
Although additional randomized trials with a larger cohort of patients are 
required, our observational study suggests improvement in function over a short?
term at a low dosage.  This would open a new window of intervention in this so 
far non?curable disease.  It should be emphasized that the benefit to risk of a long?
term treatment should be carefully evaluated due to the side effects of steroids, as 
diabetes mellitus, cataract, growth failure and osteoporosis.  In addition, an 
increased risk of infections could be related to the steroid therapy.   
It would be important to define in the near future whether a prolongation of the 
treatment will lead to the persistence of the neurological improvement.  A long?
term study with low steroid dosage would also help define the benefit to risk ratio 
of such therapeutic intervention, to limit the concern on the immunosuppressive 
effect on the susceptibility to infections of these patients. 
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CHAPTER IV 
“Immunodeficiencies associated with 
unidentified molecular defects” 
 
Despite the enormous progress that has occurred in identifying molecular causes 
of immunodeficiency, many challenges remain.   
Among the diseases for which the fundamental causes remain unknown there 
are the Hyper IgE syndrome (HIES) and recently, our group documented a 
phenocopy of the congenital form of SCID due to an inhibitory anti?lymphocytic 
autoantibody. 
 
§4.1 Alteration of IL?12R signaling related with high serum levels of IgE  
HIES is a very rare primary immunodeficiency, characterized by the high serum 
levels of IgE (>2000 IU/ml), recurring staphylococcal skin abscesses and 
pneumonia with pneumatocele formation.  Most cases are sporadic, but both 
autosomal dominant forms of HIES and autosomal recessive forms have been 
described. Skeletal symptoms such as hyperextensibility of joints, scoliosis, 
osteoporosis, and retained primary teeth are associated with the autosomal 
dominant form.  An autosomal recessive disease characterized by severe recurrent 
viral infections, extreme eosinophilia and devastating neurological complications 
that are often fatal in childhood, has been described.  Patients with the autosomal 
recessive form appear to be prone to developing autoimmune diseases.  HIES 
usually presents very early in life.  Clinical diagnosis has been based on a profile 
of immunologic and non?immunologic features leading to a composite score.  
Specific mutations have not been identified in these patients (171).   
It has been hypothesized that elevated serum levels of IgE are associated with a 
Th1/Th2 imbalance.  A Th1 response is implicated under ordinary circumstances 
in resistance to several intracellular pathogens, but an excessive Th1 response is 
associated with different autoimmune diseases, as rheumatoid arthritis (172), type 
I diabetes (173) or multiple sclerosis (174).  On the contrary, a Th2 dominated 
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response, usually involved in the response to extracellular pathogens as parasitic 
or helminths, is associated with allergic disorders and the progression of chronic 
infections as AIDS (175).   
The dimeric cytokine IL?12, produced by B cells and macrophages, plays a 
pivotal role for the induction of a Th1 response (176).  The receptor is upregulated 
during T?cell activation and IL?12Rβ2 transcript is selectively expressed in Th1 
cells following IL?12 stimulation, while IL?12Rβ1 is constitutively expressed in 
resting cells (177).  The transducing element of the receptor is the IL?12Rβ2 chain 
that functionally interacts with STAT4 (178).  Th1 cells develop in the presence 
of interleukin IL?12 and STAT4 signaling and secrete mainly IFN?γ (179).   
We investigated, at a functional level, whether an impaired induction of Th1 
response occurred in patients with elevated IgE serum levels and whether such 
abnormalities were correlated with alterations of the IL?12 receptor signaling 
apparatus.  In particular, the activation of STAT4 molecule, which follows IL?12R 
triggering, the analysis of gene transcription and membrane assembly of the 
receptor itself were investigated in allergic children divided on the basis of the 
amount of serum IgE.  We provided evidence of altered IL?12/IL?12R signaling in 
patients with very high IgE level, suggestive of an impaired Th1 induction.   
It is noteworthy that all the abnormalities herein described were observed only 
in patients with IgE levels higher than 2000 kU/l, which represent only a minority 
of patients, and not in atopic patients with an ordinary increase of IgE levels.  The 
cut off of 2000 kU/l is generally assumed as a presumptive sign to select patients 
at risk of being affected by HIES.  However, this syndrome was excluded in our 
patients by the absence of the typical clinical and immunological features (171).  
In particular, no recurrent skin infections, facial, skeletal and dentition anomalies 
were observed.   
The results of this study were published as Article on Cellular Immunology.  
See below for the paper. 
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§4.2 Conclusive remarks 
In this study, we provided evidence of altered IL?12/IL?12R signaling in patients 
with very high IgE level, suggestive of an impaired Th1 induction.      In 
particular, in this case we characterized an unappreciated relationship between an 
impairment of Th1 induction due to alteration of IL?12R signaling and high levels 
of serum IgE but in the absence of HIES.   
However, it should be noted that abnormalities of IL?12 signaling pathway is 
not sufficient per se to cause an allergic disease in children.  Our data could imply 
a pathogenic link between infections and allergy in children.  In the light of this 
consideration, a better understanding of the molecular mechanisms governing 
Th1/Th2 homeostasis may help ameliorate the overall management of these 
patients.  In fact, there is evidence that patients with severe forms of allergic 
manifestations are more susceptible to respiratory infections, and vice versa 
infections may trigger acute episodes of asthma (180).   
Overall, our results indicate that children with very high serum IgE levels have 
functional and biochemical signs of an altered IL?12/IL?12 receptor signaling 
network. 
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§ 4.3 SCID?like phenotype associated with an autoantibody 
Interestingly, evidence is emerging that, unlike total immunodeficiencies, partial 
T?cell immunodeficiencies are more frequently associated with hyperimmune 
dysregulation with a frank autoimmune phenotype (181).  Even more interesting 
the observation that the loss of function or gain of function alterations in the 
immune system functionality may arise from abnormalities of the same multiple 
genes, that in some cases lead to total and in other to partial deficiencies.  This 
would imply that the hyperimmune dysregulation is not related to selected genes 
alterations, but rather to the partial T?cell immunodeficiency itself (181).   
We reported a patient with a clinical phenotype resulting in a typical 
lymphocytopenic T?B+NK+ SCID.  A similar phenotype is generally due to an 
impairment of the T?cell differentiation process resulting in a severe reduction in 
peripheral T?cell pool size associated with molecular alterations of genes 
implicated in T?cell ontogeny and functionality (182?184).   
The patient was born at 42 weeks of gestation to unrelated healthy parents.  At 
6 months of age the child was hospitalized because of chronic diarrhoea, 
dystrophic features and febrile seizures.  At 8 months of age, the immunological 
evaluation revealed decreased IgG serum levels (<47mg/dl) and normal IgA and 
IgM.  Moreover, the patient showed an autoimmune haemolytic anemia.  At the 
time of the study, lymphocytes were 3 x 109/l, with 34.5% of CD3+ cells, 25.5% 
and 15.3% of CD4+ and CD8+, 4% of CD19+ and 15% of CD56+CD3? cells.  A 
severe lymphocyte functional impairment, in the absence of HIV or any other viral 
infection, was noted.  Patient’s PBMC exhibited absent proliferation to PHA.  To 
identify a potential inhibitory factor, the patient’s serum was added to PBMC from 
5 distinct healthy controls.  A significant higher inhibitory effect when compared 
to normal human serum was noted (Figure 14).   
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Figure 14. Inhibition (%) of normal peripheral mononuclear cells (PBMC) proliferation after 
stimulation with PHA (8 ?g/ml).  Cultures were performed in the presence of either 5% normal 
human serum or 5% SCID patient’s serum.  Bars show mean ±SD, n=5 
 
To define the potency of the inhibitory effect, scalar doses of either SCID 
patient’s serum or normal serum were used and a dose?response curve was 
obtained.  A linear increase of the inhibition was observed, reaching the maximum 
inhibition at the 10% concentration (Figure 15). 
 
 
Figure 15. [3H]thymidine incorporation by normal PBMC stimulated with PHA (8 µg/ml) and 
incubated with scalar concentrations (0, 1.25, 2.5, 5 and 10%) of either normal human serum or 
SCID patient’s serum.  Each point represents the mean ±SD, n=3.   
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Serum heat inactivation did not abolish the inhibitory effect on the proliferation 
to PHA of control PBMC (Figure 16), thus ruling out a role of the complement in 
the phenomenon.   
 
Figure 16. Effect of native and heat?inactivated serum on proliferative response by normal 
PBMC stimulated with PHA (8 µg/ml).  Before use, both patient’s and normal serum aliquots were 
heated at 56° C for 30 min to inactivate complement.  PBMC were cultured in medium containing 
10% native serum or heat?inactivated serum. Values are expressed as mean ±SD, n=3.   
 
To evaluate whether the patient's serum inhibitory effect was attributable to an 
anti?lymphocyte autoantibody, affinity purified IgG, from both patient and control 
were tested for the inhibitory property.  The patient’s purified IgG fraction was 
able to significantly inhibit the proliferative response of normal PHA?stimulated 
PBMC differently from control purified Ig fraction (Figure 17).   
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Figure 17. Inhibition by SCID patient’s Ig of proliferative response by normal PBMC 
stimulated with PHA (8 µg/ml).  Control PBMC were cultured in the presence of either 10% 
patient’s native serum or patient’s purified Ig (50 µg/ml) or in the presence of either 10% normal 
native serum or normal purified Ig (50 µg/ml), n=3.  Negative control: FCS.  Bars show means 
±SD.  * Statistically significant difference (P <.05) compared to the cultures containing control 
purified Ig fraction.  
 
The patient also developed a severely progressive active autoimmune hepatitis, 
treated with azathioprine (AZA) (1.5 mg/kg/day) and steroids.  A paradoxical 
effect of immunosuppression on cell subsets was noted in that, an increase of the 
CD3+ and CD4+ occurred.  Differently, CD19+ and CD8+ cells didn’t change 
significantly during the therapy (Figure 18). 
 
Figure 18. Increase in the percentage of major lymphocyte subsets in the SCID patient during 
the treatment with azathioprine (AZA) and steroids.  PBMC from the SCID patient were stained 
using anti?CD3, anti?CD4, anti?CD8 and anti?CD19 antibodies and analyzed by fluorescence 
activated cell sorter (FACS).  The horizontal lines indicate the period of immunosuppressive 
treatment with AZA (dotted line) and steroids (solid line). 
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In conclusion, this SCID?like patient was characterized by a severe T?cell 
activation deficiency, in whose serum an inhibitory factor, precipitated in the 
purified Ig fraction and able to potently inhibit control cells proliferation, was 
identified.  So far, an autoreactive anti?lymphocyte antibody able to induce a SCID 
phenocopy has never been described.   
The results of this study were published on Journal of Investigational 
Allergology & Clinical Immunology.   
 
§ 4.4 Conclusive remarks 
We documented in a SCID?like phenotype a novel pathogenetic mechanism due to 
an inhibitory anti?lymphocytic autoantibody, resulting in a total T?cell activation 
deficiency associated with autoimmunity.  This complex phenotype represents a 
phenocopy of the congenital forms of SCID.   
Our data indicate a direct role of the antibody as negative regulator of T?cell 
functionality.  However, it is also possible that the inhibitory autoantibody in our 
patient is the consequence of a hyper immune dysregulation rather than the cause 
of the T?cell defect, whose genetic alteration still remains to be identified.  
Although the functional defect observed in our patient may theoretically be related 
to viral induced anergy (185), no viral infection was documented and the 
functional defect was total differently from what observed in viral induced anergy.  
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TECHNOLOGIES 
 
§ Cells and cell cultures 
Peripheral Blood Mononuclear cells (PBMC) were obtained from patients and 
healthy donors by Ficoll?Hypaque (Biochrom) density gradient centrifugation.   
B lymphoblastoid cell lines (BCLs) were generated by EBV immortalization of 
patients and healthy donors PBMC using standard procedures.   
The human T?acute lymphoblastic leukemia cell line (Molt?4), the chronic 
myelogenous leukemia cell line (K?562), Burkitt lymphoma cell line and its 
isogenic derivatives (Raji and Rj225) were grown in RPMI?1640 (Lonza, 
Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS; Gibco), 2 
mmol/L L?glutammine (Gibco), and 50 ?g/ml gentamycine (Gibco), and cultured 
at 37°C, 5% CO2.  Serum starvation was used to synchronize tumor cells in the 
G0/G1?phase of the cell cycle.  The cells were incubated in medium without FBS 
for 24 hours.  In self?sufficient growth experiments, cells were cultured in 
DMEM/F12 (Lonza) without FBS and supplemented with 2 mmol/L L?
glutammine.   
Primary leukemic cell lines, consisting of acute lymphoblastic leukemia (ALL) 
cells, were obtained from aspirated bone marrow of 3 patients.  Normal bone 
marrow cells were obtained from healthy donors and used as control cells.   
Cord blood mononuclear cells (CBMCs) were isolated from Nude/SCID fetus 
and control human fetus, matched for the same gestational age, by density 
gradient centrifugation over Ficoll?Hypaque (Biochrom), after written consent.  
Cell suspensions were prepared in RPMI 1640 medium. 
 
§ Genetic counseling 
A genetic counseling program was offered to the village population from which 
the proband affected with the Nude/SCID phenotype was originated.  Since 
FOXN1 mutation is particularly devastating, because it leads to the absence of the 
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thymus and SCID, prenatal diagnosis by direct genetic analysis was performed for 
couples at risk.   
 
§ A?T patients and study design.  
Six A?T patients (3 males and 3 females) were selected because they were 
responsive to a full betamethasone dosage of 0.1 mg/kg/day and enrolled into this 
study.  The patients received a diagnosis of A?T according to the European 
Society of Immunodeficiencies (ESID) criteria.  A previous molecular study 
revealed a mutation of ATM in all patients, resulting in the absence of the protein 
in five patients and a decrease to 20% in the remaining patient (P2).  
The patients, upon informed consent, received two subsequent 20?day?cycles 
of oral betamethasone at the dosage of 0.01 and 0.03 mg/kg/day, divided every 12 
h, corresponding to 10 and 30 % of the dosage used in a previous study.  The two 
cycles were separated by an off?therapy 20?day?period as a wash?out phase.  
Clinical and laboratory evaluations were carried out at baseline (T0), at the end of 
the first cycle of therapy with 0.01 mg/kg/day (T20), before beginning the second 
cycle of therapy (T40), at the end of the second cycle of therapy with 0.03 
mg/kg/day (T60) and 20 days after the withdrawal (T80).  Neurological 
assessment was performed by means of the Scale for the Assessment and Rating 
of Ataxia (SARA) (see appendix E1 on the Neurology Web site at 
http://www.neurology.org/cgi/content/full/66/11/1717/DC1).  Each clinical 
neurological examination was videotaped in the presence of 2 pediatric 
neurologists.  A third physician reviewed the videotape blinding.  The final results 
were obtained through the comparison of the individual evaluators’ scores.  
During the treatment period, all patients underwent general physical examinations 
while potential adverse effects were being monitored through routine laboratory 
tests, including blood cell count, serum levels of transaminases, plasma electrolyte 
levels, renal functionality.   Furthermore, weight and blood pressure were 
measured.  The protocol was formally approved by the Ethical Committee for 
Biomedical Activities of “Federico II” University (trial registration n. 185/08). 
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§ Subjects with elevated IgE levels 
Twenty patients with elevated IgE levels and history of allergy were enrolled into 
the study.  Sixteen patients were affected by asthma, 3 of them also by rhinitis, 
and 4 had a history of atopic dermatitis.  The patients divided in two subgroups on 
the basis of IgE levels: group A consisted of 10 patients, 10 males, range of age 5?
15 years, with very high serum IgE levels (>2000kU/l, range 2152?5000 kU/l); 
group B consisted of 10 patients, 9 males, range of age 6?15 years, with high 
serum IgE levels (IgE value between the age specific mean±2SD and 2000 kU/l, 
range 93?1152 kU/l).  Twenty healthy controls, 16 males range of age 6?15 years 
(IgE range 85?100 kU/l), were also studied.  Informed consent was obtained when 
required.  All patients enrolled into the study didn’t receive any treatment, 
including steroid or non?steroid drugs, in the month before entering into the study.  
No difference was found between group A and B in either the number per year or 
the severity of allergic manifestations.  In all patients, the clinical features 
persisted for more than 2 years. 
The Hyper?IgE syndrome (HIES) was excluded by the absence of typical 
clinical and immunological features according to the clinical score for HIES.  In 
particular, no recurrent skin infections, facial, skeletal and dentition anomalies 
were observed.  Other conditions accompanied by elevated serum IgE 
concentration, including AIDS, helminths and parasitic infections were also 
excluded by clinical and laboratoristic features. 
The study has been approved by the Institutional Review Board. 
 
§ SCID?like patient’s profile 
The patient was born at 42 weeks of gestation to unrelated healthy parents.  At 8 
months of age, the patient showed an autoimmune haemolytic anemia and a 
progressive decline of CD4+ cells, resulting in a typical lymphocytopenic form of 
severe combined immunodeficiency.  At the time of the study, lymphocytes were 3 
x 109/l, but a severe lymphocyte functional impairment in the absence of HIV or 
any other viral infection was first noted as above described.  IL?2Rγ alterations 
were ruled out.  Thereafter, 2 bronchopneumonia and an interstitial pneumopathy 
 8?
occurred despite intravenous Ig replacement therapy and anti?infectious agents.  
Autoreactive antibodies toward smooth muscle, red and white cells were detected.  
During the follow?up, the patient developed a severely progressive active 
autoimmune hepatitis, diagnosed according the AIH international score, treated 
with Azathioprine (AZA) (1.5 mg/kg/day) and steroids.  At 4 years of age the 
patient died of disseminated interstitial pneumopathy, while the search for a HLA?
matched donor was still pending.   
 
§ siRNA transfection 
The validated chemically modiﬁed oligonucleotides used as siRNA for IL2RG or 
random non?silencing nucleotides with no known specificity siRNA, used as 
negative control, were obtained from Invitrogen (Paisley, UK).  These siRNAs 
were transfected at a concentration of 200 pmol/1x106 cells in a six well plate for 
96 hours.   The transfection was performed by the lipid vector Lipofectamine 
2000 kit (Invitrogen, Paisley, UK), according to the manufacturer’s instructions.  
Preliminary experiments were performed to establish the silencing efficiency by 
testing two different oligonucleotides obtained from Invitrogen (Paisley, UK).  
The amount of protein expression reduction was calculated as follows: 1? 
(ODsiRNA x 100 / ODcontrol siRNA).  
In self?sufficient growth experiments, BCLs were cultured in Dulbecco 
modified Eagle medium (DMEM)/F12 without FBS and supplemented with 2 
mM/L L?glutamine.  
  
§ Proliferative assay 
Cell proliferation was analyzed by the CFSE dilution assay.  Cells (1x106) were 
resuspended in 1 ml PBS?10% FBS and labeled with 1.7 ?M CFSE (Molecular 
Probes).  After 2 min in the dark at room temperature, cells were washed in FBS 
and PBS.  After 6 hours cells were analyzed on a FACSCalibur flow cytometer 
using CellQuest software (BD Biosciences). 
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Cell viability was determined using trypan blue staining.  Cell survival was 
evaluated following stimulation with anti?Fas mAb (400 ng/ml; Upstate) for 6 
hours. 
Cell proliferation was also analyzed by the thymidine incorporation assay.  
For the evaluation in vitro of proliferative response to mitogens of PMBC and 
CBMC, cells were stimulated with phytohaemagglutinin (PHA; 8 ?g/ml), 
concanavalin A (ConA; 8 ?g/ml), pokeweed (PWM, 10 ?g/ml) (Difco 
Laboratories), phorbol?12?myristate?13?acetate (PMA; 20 ng/ml) and ionomycin 
(0.5 mM) (Sigma Chemical Co).  CD3 cross?linking (CD3 X?L) was performed 
by precoating tissue culture plates with 1 and 0.1 ng/ml purified anti?CD3 
monoclonal antibody (Ortho Diagnostic).   
To evaluate allogeneic response in patients with elevated IgE levels, cells (1 x 
105) were stimulated with an equal amount of irradiated stimulator cells from 
controls in a standard one?way mixed lymphocyte reaction assay.   
Cells were plated in triplicate at 1x105 viable cells/well in 96?well plates (BD 
Biosciences), in 200 ?l of complete medium for 4 days.  Cultures were pulsed 
with 0.5 ?Ci 3H?thymidine for 8 hours before harvesting and the incorporated 
radioactivity measured by scintillation counting.   
In a few experiments complement components were inactivated through 
heating of serum samples at 56° C for 30 min before use.  The percentage of 
inhibitory activity in the sera was calculated from the formula: (cpm of PHA?
stimulated cultures containing 5% tested serum/cpm of PHA?stimulated cultures 
containing 5% FCS) x 100.  Patients and normal IgG were purified using a protein 
G column according to the vendor’s instructions (Pharmacia Biotech). 
 
§ Reagents, western blot and immuneprecipitation 
Recombinant human GH (rGH) was obtained from Serono (Saizer 4).  The 
enhanced chemiluminescence (ECL) kit was purchased from Amersham 
Biosciences.  The Abs anti?γc, anti?JAK3, anti?beta?actin, anti?Bcl?2, anti?Bcl?XL, 
anti?histone 3 (H3), anti?phosphotyrosine, anti?STAT5, anti?STAT4 were 
purchased from Santa Cruz Biotechnology.  The Ab anti?caspase 3 was purchased 
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from Cell Signaling Technology.  Acrylamide and bisacrylamide were obtained 
from Invitrogen.  Prestained molecular mass standards were obtained from Bio?
Rad.  Except where noted, other reagents were from Sigma?Aldrich.   
Stimulated or unstimulated cells were washed with ice?cold phosphate buffer 
saline (PBS; Cambrex, Charles City, IA) and lysed in 100 ?l of lysis solution 
containing 20 mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P?40, 10 mM EDTA, 
1 mM phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum (Na3VO4), 5 
?g/ml leupeptin and 5 ?g/ml aprotinin on ice for 45 min.  The cell lysates were 
stored at ?80°C until processing.  Proteins were separated on 12% SDS?PAGE.  
The membrane was then washed three times in wash buffer and incubated 1 h at 
room temperature or overnight at 4°C with the specific Ab. The membrane was 
then washed three times and an appropriate IgG HRPconjugated secondary Ab 
was used for the second incubation. After further washings, the membrane was 
developed with ECL?developing reagents, and exposed to x?ray films according to 
the manufacturer’s instructions (Amersham Biosciences).   
For immunoprecipitation, lysates were normalized for either protein content or 
cell number and precleared with protein G agarose beads (Amersham 
Biosciences).  The supernatant was incubated with 2 microg/ml anti?JAK3 or 
polyclonal serum, followed by protein G agarose beads.  The immunoprecipitates 
were separated on density gradient gels, followed by Western blotting.  Proteins 
were detected using antibody for phosphotyrosine.  
Densitometric analysis was performed after background equalization through 
the ImageJ software.    
 
§ Confocal microscopy 
After appropriate stimulation, as indicated, cells were fixed in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 min at room 
temperature and centrifuged in a Shandon Cytospin III (Histotronix) onto a glass 
slide and permeabilized by incubation in a 0.2% Triton X?100 solution for 20 min.  
BCLs were incubated for 1 h at room temperature with rabbit anti?STAT5 Ab in 
PBS containing 1% BSA.  After four washings for 5 min in PBS, the cells were 
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incubated for 1 h at room temperature with FITC?conjugated donkey anti?rabbit 
IgG (Pierce) in PBS. After washing in PBS, the glass slides were mounted under a 
coverslip in a 5% glycerol PBS solution. The slides were analyzed by laser 
scanning confocal microscopy using a Zeiss LSM 510 version 2.8 SP1 Confocal 
System (Zeiss).  At least 100 cells per condition were analyzed in each experiment 
to determine the rate of STAT5 nuclear translocation. 
 
§ Brain alterations evaluation in Nude/SCID fetus 
The abdominal sonography was performed through GE Voluson E8 Ultrasound 
Machine.  Brain MRI study was performed at 3 Tesla (Magnetom TRIO, Siemens, 
Germany) using a 3D low?angle, gradient?echo sequence (TR/TE 572/3.7 msec, 
FA 9°, FOV150mm, acquisition matrix 144x256, slice thickness 600mm, using a 
quadrature volumetric coil) providing a T1w volume which was resliced along 
axial, coronal and sagittal planes.  Images were processed using GIMP 
(http://www.gimp.org) to remove paraformaldehyde background.   
 
§ PCR and quantitative real?time PCR analysis  
After a written informed consent was obtained from parents of Nude/SCID fetus, 
genomic DNA was extracted by standard procedures from villous and processed.  
FOXN1 DNA analysis was performed according to a polymerase chain reaction 
(PCR) assay previously described.  Briefly, a PCR fragment containing exon 4 of 
the FOXN1 gene (formerly named exon 5) was amplified using the primers exon 
5F: 5?CTTCTGGAGCGCAGGTTGTC?3 and exon 5R: 5?
TAAATGAAGCTCCCTCTGGC?3.  The PCR product was sequenced using an 
ABI prism 310 Genetic Analyzer (Applied Byosystems Inc.). 
Total RNAs were extracted using TRIzol reagent (Invitrogen) in accordance 
with the manufacturer’s instructions.   
To evaluate the effect of γc on cell survival and proliferation, RNA was 
reverse?transcribed in the presence of SuperScript II RT (Invitrogen) and 
oligo(dT) primers (Invitrogen) at 50°C for 50 min and then at 85°C for 5 min to 
inactivate the enzymes.  Amplification of the cDNAs was performed using the 
 87
S?BR Green and analyzed with the Light Cycler480 (Roche).  Primers are listed 
in Table 1.  The PCR conditions comprised an initial denaturation at 94°C for 5 
min, followed by 35 cycles at 62°C for 20 s and 72°C for 5 min.  A dissociation 
procedure was performed to generate a melting curve for confirmation of 
amplification specificity.  The results were normalized to beta?actin.  The relative 
levels of gene expression are represented as ??Ct=(Ctgene?Ctreference) and the fold 
change in gene expression was calculated by the 2???Ct method (where Ct is cycle 
threshold), as previously described. 
 
Gene Primers sequence 5'?3' 
Bcl?XL 
 
5'?GTAAACTGGGGTCGCATTGT?3' 
5'?TGCTGCATTGTTCCCATAGA?3' 
Cyclin D1 
 
5'?AGGTCTGCGAGGAACAGAAGTG?3' 
5'?TGCAGGCGGCTCTTTTTC?3' 
Cyclin D2 
 
5'?CTGTGTGCCACCGACTTTAAGTT?3' 
5'?GATGGCTGCTCCCACACTTC?3' 
Cyclin D3 
 
5'?GCAGCGCCTTTCCCAACT?3' 
5'?TCAAAAGGAATGCTGGTGTATGTATC?3' 
Cyclin A2 
 
5'?CTGCTGCTATGCTGTTAGCC?3' 
5'?TGTTGGAGCAGCTAAGTCAAAA?3' 
Cyclin B1 
 
5'?CGGGAAGTCACTGGAAACAT?3' 
5'?AAACATGGCAGTGACACCAA?3‘ 
IL?2Rγ 
 
5'?TGCTAAAACTGCAGAATCTGGT?3' 
5'?AGCTGGGATTCACTCAGGTTTG?3' 
Beta?actin 
 
5'?GACAGGATGCAGAAGGAGAT?3' 
5'?GACAGGATGCAGAAGGAGAT?3' 
 
Table 1. Primers used for real?time qRT?PCR 
 
To evaluate GR and GILZ expression levels, reverse transcriptase was done 
using QuantiTect Reverse Trascription (Qiagen). For real?time PCR, sense primer 
for GILZ was 5'?AGGGGATGTGGTTTCCGTTA?3', and antisense 5'? 
TGGCCTGTTCGATCTTGTTG?3'.  For GR, sense: 5'? 
AACTGGAATAGGTGCCAAGG ?3'; antisense: 5'? 
 88
GAGCTGGATGGAGGAGAGC ??'. For HPRT, sense: 5'? 
TGGCGTCGTGATTAGTGATG?3', antisense: 5'? 
GCACACAGAGGGCTACAATG ?3'.  PCR was done in CHROMO 4 (MJ 
Research Bio Rad) using DyNAmo HS SYBR Green qPCR kit (Finnzymes; 
Celbio).  Relative amounts of GILZ, L?GILZ and GAPDH mRNA were 
calculated by the Comparative ??C(t) method. C(t) values were determined using 
the Opticon Monitor 2 software (MJ Research Bio Rad). 
To evaluate IL?12Rβ2 chain expression, RNA was reverse transcribed into 
cDNA using ExpandTM Reverse transcriptase according to the manufacturer's 
protocol (Boehringer Manneheim).  The cDNA was PCR amplified (94°C, 1 
minute; 55°C, 1 minute; 72°C,1 minute for 30 cycles) using specific primers for 
IL?12Rβ2: sense primer GGAGAGATGAGGGACTGGT and antisense primer 
TCACCAGCAGCTGTCAGAG.  To monitor the amount of RNA, β?actin mRNA 
expression was used.  PCR products were separated in a 1% agarose gel and 
viewed after ethidium bromide staining.  
 
§ Microsatellite analysis 
To test maternal contamination, multiplex?PCR of 15 highly polymorphic 
autosomal short tandem repeat loci (D8S1179, D21S11, D7S820, CSF1PO, 
D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWA, TPOX, 
D18S51, D5S818, FGA) was performed on DNA samples from cord blood using 
AmpFlSTR® Identifiler™ PCR Amplification Kit (Applied Biosystems). 
 
§ Flow cytometry analysis 
CBMC of Nude/SCID fetus were stained with the appropriate antibodies (CD45, 
CD3, CD8α, CD4, TCRαβ, TCRγδ, CD45RA (BD Pharmingen) on ice, washed 
and analyzed using a FACSCanto II flowcytometer Becton Dickinson.  Data were 
analyzed using FACSDiva software.  
The following conjugated monoclonal antibodies with appropriate isotype? and 
fluorochrome?matched isotype controls were used in one?colour or two?colour 
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staining: anti?CD3 (Leu?4), anti?CD8 (Leu?2a), anti?CD4 (Leu?3a) and anti?CD19 
(Leu?12) (Becton Dickinson).  After immunostaining, PBMC isolated from SCID?
like patient were analyzed on a fluorescence activated cell sorter (FACSCalibur) 
(Becton Dickinson) using CellQuest (Becton Dickinson) software.  PBMC were 
gated on the basis of linear forward and side scatter characteristics.  Each 
lymphocyte subset was expressed as a percentage of positive cells. 
 
§ Evaluation of TCR Vβ repertoire 
T cells were separated into CD4+ and CD4? cells by magnetic sorting with coated 
beads (Dynabeads).  RNA was prepared with Trizol (Gibco) according to the 
manufacturer’s instructions.  For Spectratyping analysis, 400 ng of total RNA 
were retrotranscribed and amplified in a single?step reaction with the 
SuperScript™ III One?Step RT?PCR System with Platinum Taq DNA Polymerase 
(Invitrogen).  The same primers were used both for reverse transcription and for 
amplification.  TCR CDR3β sequencing was performed after TCR β?chain 
amplification with a common reverse primer (CB3 primer) and 27 different 
forward primers (TCR Vβ gene family primers), as described.  An initial step of 
reverse transcription at 45°C for 30 min was followed by amplification, for a total 
of 35 cycles. Cycling conditions were: 30 s at 94˚C for denaturation, 30 s at 55˚C 
for annealing, and 30 s at 72˚C for the extension with a final extension of 10 min 
at 72˚C.  PCR products were then run on a CEQ 8000 automatic capillary 
sequencer (Beckman Coulter) and fractionated on the size of the CDR3 region, as 
described.  Results were analyzed using CEQ 8000 software (Beckman Coulter).  
Vβ families were considered normal when showing 5 or more peaks with a 
gaussian distribution. 
 
§ Generation of Th1?cell lines  
Th1 cell lines were generated by stimulating PBMC with PHA (8 ?g/ml) or, in a 
few experiments, with PHA + IFN?γ (1000 U/ml, ICN, Biomedical, OH) for 72 
hours in complete tissue culture medium.  These cells usually widely express high 
affinity IL?12R. 
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§ Membrane expression of β1 and β2 chains of IL?12R on T cells 
After washing in PBS, cells were incubated for 20 minutes sequentially with 
murine anti?β1 or anti?β2 chain (25 ?l) of IL?12R (kindly provided by Dr. Jerome 
Ritz, Dana Farber Cancer Institute, Boston, MA), IgG1 isotype control Ab, 10 ?l 
FITC?conjugated goat anti?mouse IgG Ab (Becton Dickinson, San Jose, CA), and 
5 ?l anti?CD4 PE Ab (Becton Dickinson, San Jose, CA).  After staining, the 
expression of IL?12Rβ1 and β2 on CD4+ cells was determined with flow 
cytometer (Becton Dickinson) by gating on the CD4+ population.   
 
§ Statistical analysis 
All statistical analyses were performed using GraphPad Prism 4.00 and MedCalc 
for Windows.  All data were expressed as mean ± standard deviation.  Values of p 
< 0.05 were considered statistically signiﬁcant. 
In general, the significance of differences was evaluated by Wilcoxon rank sum 
test for unpaired data and student’s two tailed t?test.  The correlations were 
obtained using the Pearson’s correlation.  Inter?rater agreement was calculated 
through Weighted Kappa?coefficient. To assess the reliability of SARA score we 
also evaluated intra?class correlation coefficient (ICC).   
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SUMMARY 
 
Primary immunodeficiencies comprise more than 200 different disorders that 
affect the development and the functions of the immune system.  Many scientific 
papers have been published on the molecular and cellular basis of the immune 
response and on the mechanisms involved in the correct development of immune 
system components.  Although today we know the genetic and molecular basis of 
those principal mechanisms involved in the immune response, some aspect in this 
field remain unclear.   
In this thesis, during the three years of my PhD program, I have contributed to 
elucidate “New insights and unsolved issues in congenital immunodeficiencies”, 
through the combination of clinical, cellular, functional and molecular 
approaches.    
In particular, my research work is focused on the study role of γc in cell cycle 
progression, strongly related to its cellular amount and GH?R signaling, defining 
the basis of the physiological interaction between endocrine and immune systems.  
I demonstrate, moreover, that this subunit is able to influence the cell cycle 
progression in a concentration dependent manner in lymploblastoid and neoplastic 
cell lines. 
Moreover, I participated to better define the functional role of FOXN1 
transcription factor in the development of the T?cell ontogeny in the Nude/SCID 
syndrome.  I also documented that FOXN1 is a possible cofactor in the 
development and differentiation of some structures in the central nervous system.  
Of note, this immunodeficiency is due to mutated gene expressed in non 
hematopoietic cells. 
In addition, I participated to the study of patients affected with A?T.  In this 
context I contributed to evaluate the beneficial effect of betamethasone on therapy 
in these patients.  Our data indicate that betamethasone is effective in A?T at a 
minimal dosage and that GILZ may be a useful biomarker of the clinical response.   
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Finally, I also participate to give a contribution to the description of new 
mechanism in immunodeficiencies associated with unidentified molecular defects.  
Our data revealed that in a group of patients with high levels of serum IgE the IL?
12R signaling was altered.  Moreover, we documented the possibility of an 
autoreactive anti?lymphocyte antibody able to induce a SCID phenocopy.   
Overall, all my studies were designed in order to clarify unsolved issues and 
unknown mechanisms underlying the functionality of the immune system.   These 
results could be useful both in the clinical practice and in the basic research of 
immunedeficiencies.   
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ABBREVIATIONS 
 
ADA = adenosine deaminase  
APC = antigen presenting cells  
AK2 = adenylate kinase 2 
ALL = acute lymphoblastic leukemia 
A?T = ataxia?telangiectasia 
ATM = ataxia telangiectasia mutated 
AZA = azathioprine 
BCL = b cell line 
BMP = bone morphogenetic protein 
BMT = bone marrow transplantation 
CNS = central nervous system  
CNTF = ciliary neurotrophic factor 
CSP = cavum septum pellucidum  
DC = dyskeratosis ? ongenital  
DN = double negative 
DP = double positive 
DSB = double?strand break  
FOX = forkhead box  
FGF = fibroblast growth factor 
γc = common gamma chain 
GC = glucocorticoid 
GH = growth hormone  
GHR = growth hormone receptor 
GS?CSF = granulocyte?macrophage colony?stimulating factor 
GILZ = glucocorticoid?induced leucine zipper 
GRE = glucocorticoid responsive element 
GVHD = graft?versus?host?disease 
HIES = hyper ige syndrome 
HPC = hematopoietic precursor cell 
IGF = insulin growth factor 
IL = interleukin 
IRS = insulin receptor substrate 
ISP = immature single positive 
JAK = janus associated kinase  
KGF = keratinocyte growth factor  
LIF = leukemia inhibitory factor 
MAPK = mitogen?activated protein kinase 
MRI = magnetic resonance imaging  
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NK = natural killer  
OSM = oncostatin m 
PBMC = peripheral blood mononuclear cell 
PI3K = phosphatidyl inositol 3 kinase  
PK = protein kinase  
PTP = tyrosine?protein phosphatase 
RAG = recombinase activating gene 
ROS = reactive oxygen species  
RTE = recent thymic emigrant 
SARA = scale for the assessment and rating of ataxia 
SCID = severe combined immunodeficiency 
SHP = sh2 domain?containing protein?tyrosine phosphatase 
siRNA = short interfering rna  
SOCS = suppressors of cytokine signaling 
SP = single positive 
STAT = signal transducers and activators of transcription 
TCR = t cell receptor  
TEC = thymic epithelial cell  
TGF = tumor growth factor 
TNF = tumor necrosis factor 
Wnt = wingless 
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